Synthetic lethality as a new concept for the treatment of cancer;Synthetische Letalität als Therapiekonzept für die Behandlung maligner Neoplasien

Deutsche Medizinische Wochenschrift

Volumn 136, Issue 30, 2011, Pages 1526-1530

  Herter Sprie, G S ^a,b   Chen, S ^a,b   Hopker K ^a   Reinhardt, H C ^a,b,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

cancer; oncogene; synthetic lethality; tumor suppressor gene

Indexed keywords

ARTICLE; CANCER THERAPY; SYNTHETIC LETHALITY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; DNA REPAIR; EPISTASIS, GENETIC; FEMALE; HUMANS; NEOPLASMS; ONCOGENES; OVARIAN NEOPLASMS; PHENOTYPE; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION;

EID: 79960751064     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0031-1281549     Document Type: Article

References (30)

1. Audeh M W., Carmichael J, Penson R T. et al,. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010 376 245-251
2. Bryant H E., Schultz N, Thomas H D. et al,. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005 434 913-917 (Pubitemid 40559005)
3. Dickgreber N, Huber R M., Reck M et al,. Aktuelle Entwicklungen und Perspektiven zielgerichteter Therapien. Onkologie 2010 33 Suppl 5 2-11
4. Dohner H, Stilgenbauer S, Benner A et al,. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000 343 1910-1916 (Pubitemid 32064784)
5. Dumont F, Altmeyer A, Bischoff P. Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches. Expert Opin Ther Pat 2009 19 775-799
6. Edwards S L., Brough R, Lord C J. et al,. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008 451 1111-1115 (Pubitemid 351317441)
7. Farmer H, McCabe N, Lord C J. et al,. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005 434 917-921 (Pubitemid 40559006)
8. Fong P C., Boss D S., Yap T A. et al,. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009 361 123-134
9. Greenman C, Wooster R, Futreal P A., Stratton M R., Easton D F. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics 2006 173 2187-2198 (Pubitemid 44285695)
10. Gurley K E., Kemp C J. Synthetic lethality between mutation in Atm and DNA-PK(cs) during murine embryogenesis. Curr Biol 2001 11 191-194 (Pubitemid 32152105)
11. Hanahan D, Weinberg R A. Hallmarks of cancer: the next generation. Cell 2011 144 646-674
12. Hoeijmakers J H. Genome maintenance mechanisms for preventing cancer. Nature 2001 411 366-374 (Pubitemid 32467046)
13. Jiang H, Reinhardt H C., Bartkova J et al,. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009 23 1895-1909
14. Kaelin Jr W G. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005 5 689-698 (Pubitemid 41486362)
15. Luo J, Emanuele M J., Li D et al,. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009 137 835-848
16. Martin S A., Lord C J., Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008 18 80-86 (Pubitemid 351694447)
17. Martins C P., Brown-Swigart L, Evan G I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006 127 1323-1334 (Pubitemid 44960417)
18. Meindl A, Hellebrand H, Wiek C et al,. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010 42 410-414
19. OShaughnessy J, Osborne C, Pippen J E. et al,. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011 364 205-214
20. Reinhardt H C., Aslanian A S., Lees J A., Yaffe M B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007 11 175-189 (Pubitemid 46209849)
21. Reinhardt H C., Hasskamp P, Schmedding I et al,. DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization. Molecular Cell 2010 40 34-49
22. Reinhardt H C., Jiang H, Hemann M T., Yaffe M B. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 2009 8 3112-3119
23. Reinhardt H C., Yaffe M B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009 21 245-255
24. Scholl C, Frohling S, Dunn I F. et al,. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009 137 821-834
25. Soda M, Choi Y L., Enomoto M et al,. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 448 561-566 (Pubitemid 47206930)
26. Tutt A, Robson M, Garber J E. et al,. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010 376 235-244
27. Tutt A N., Lord C J., McCabe N et al,. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005 70 139-148 (Pubitemid 44124865)
28. Ventura A, Kirsch D G., McLaughlin M E. et al,. Restoration of p53 function leads to tumour regression in vivo. Nature 2007 445 661-665 (Pubitemid 46232887)
29. Wood L D., Parsons D W., Jones S et al,. The genomic landscapes of human breast and colorectal cancers. Science 2007 318 1108-1113 (Pubitemid 350134889)
30. Xue W, Zender L, Miething C et al,. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007 445 656-660 (Pubitemid 46232886)